Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Zmień bibliotekę

Wyszukujesz frazę ""COVID-19 Vaccines"" wg kryterium: Temat


Tytuł :
Design and proof of concept for targeted phage-based COVID-19 vaccination strategies with a streamlined cold-free supply chain.
Autorzy :
Staquicini DI; Rutgers Cancer Institute of New Jersey, Newark, NJ 07101.; Division of Cancer Biology, Department of Radiation Oncology, Rutgers New Jersey Medical School, Newark, NJ 07103.
Tang FHF; Rutgers Cancer Institute of New Jersey, Newark, NJ 07101.; Division of Cancer Biology, Department of Radiation Oncology, Rutgers New Jersey Medical School, Newark, NJ 07103.
Markosian C; Rutgers Cancer Institute of New Jersey, Newark, NJ 07101.; Division of Cancer Biology, Department of Radiation Oncology, Rutgers New Jersey Medical School, Newark, NJ 07103.
Yao VJ; Rutgers Cancer Institute of New Jersey, Newark, NJ 07101.; Division of Cancer Biology, Department of Radiation Oncology, Rutgers New Jersey Medical School, Newark, NJ 07103.
Staquicini FI; Rutgers Cancer Institute of New Jersey, Newark, NJ 07101.; Division of Cancer Biology, Department of Radiation Oncology, Rutgers New Jersey Medical School, Newark, NJ 07103.
Dodero-Rojas E; Center for Theoretical Biological Physics, Rice University, Houston, TX 77005.
Contessoto VG; Center for Theoretical Biological Physics, Rice University, Houston, TX 77005.; Department of Physics, Institute of Biosciences, Humanities and Exact Sciences, São Paulo State University, São José do Rio Preto, SP 15054, Brazil.
Davis D; Rutgers Cancer Institute of New Jersey, Newark, NJ 07101.; Division of Cancer Biology, Department of Radiation Oncology, Rutgers New Jersey Medical School, Newark, NJ 07103.
O'Brien P; Rutgers Cancer Institute of New Jersey, Newark, NJ 07101.; Division of Cancer Biology, Department of Radiation Oncology, Rutgers New Jersey Medical School, Newark, NJ 07103.
Habib N; Rutgers Cancer Institute of New Jersey, Newark, NJ 07101.; Division of Cancer Biology, Department of Radiation Oncology, Rutgers New Jersey Medical School, Newark, NJ 07103.
Smith TL; Rutgers Cancer Institute of New Jersey, Newark, NJ 07101.; Division of Cancer Biology, Department of Radiation Oncology, Rutgers New Jersey Medical School, Newark, NJ 07103.
Bruiners N; Public Health Research Institute, Rutgers New Jersey Medical School, Newark, NJ 07103.
Sidman RL; Department of Neurology, Harvard Medical School, Boston, MA 02115.
Gennaro ML; Public Health Research Institute, Rutgers New Jersey Medical School, Newark, NJ 07103.
Lattime EC; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ 08901.; Department of Surgery, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ 08901.
Libutti SK; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ 08901.; Department of Surgery, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ 08901.
Whitford PC; Department of Physics and Center for Theoretical Biological Physics, Northeastern University, Boston, MA 02115.
Burley SK; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ 08901.; RCSB Protein Data Bank and Institute for Quantitative Biomedicine, Rutgers, The State University of New Jersey, Piscataway, NJ 08854.; Department of Chemistry and Chemical Biology, Rutgers, The State University of New Jersey, Piscataway, NJ 08854.; RCSB Protein Data Bank, San Diego Supercomputer Center and Skaggs School of Pharmacy & Pharmaceutical Sciences, University of California San Diego, La Jolla, CA 92067.
Onuchic JN; Center for Theoretical Biological Physics, Rice University, Houston, TX 77005; .; Department of Biosciences, Rice University, Houston, TX 77005.; Department of Chemistry, Rice University, Houston, TX 77005.; Department of Physics and Astronomy, Rice University, Houston, TX 77005.
Arap W; Rutgers Cancer Institute of New Jersey, Newark, NJ 07101; .; Division of Hematology/Oncology, Department of Medicine, Rutgers New Jersey Medical School, Newark, NJ 07103.
Pasqualini R; Rutgers Cancer Institute of New Jersey, Newark, NJ 07101; .; Division of Cancer Biology, Department of Radiation Oncology, Rutgers New Jersey Medical School, Newark, NJ 07103.
Pokaż więcej
Źródło :
Proceedings of the National Academy of Sciences of the United States of America [Proc Natl Acad Sci U S A] 2021 Jul 27; Vol. 118 (30).
Typ publikacji :
Evaluation Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms :
Immunization Programs*/methods
Bacteriophages/*genetics
COVID-19/*prevention & control
COVID-19 Vaccines/*administration & dosage
Administration, Inhalation ; Animals ; COVID-19 Vaccines/chemistry ; COVID-19 Vaccines/immunology ; Dependovirus/genetics ; Drug Storage ; Female ; Immunogenicity, Vaccine ; Mice ; Mice, Inbred BALB C ; Proof of Concept Study ; Temperature
Czasopismo naukowe
Tytuł :
Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents.
Autorzy :
Frenck RW Jr; From Cincinnati Children's Hospital, Cincinnati (R.W.F.); Kaiser Permanente Vaccine Study Center, Oakland (N.P.K.), and the California Research Foundation, San Diego (D.M.B.) - both in California; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development, Pfizer, Pearl River (A.G., J.A., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.), and SUNY Upstate Medical University, Syracuse (S.J.T.) - both in New York; Vaccine Research and Development (J.L.P., H.M., X.X.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Duke Human Vaccine Institute, Durham, NC (E.B.W.); Senders Pediatrics, South Euclid, OH (S.S.); Clinical Research Professionals, Chesterfield, MO (T.J.); BioNTech, Mainz, Germany (Ö.T., U.Ş.); and Worldwide Safety, Safety Surveillance and Risk Management, Pfizer, Groton, CT (D.B.T.).
Klein NP; From Cincinnati Children's Hospital, Cincinnati (R.W.F.); Kaiser Permanente Vaccine Study Center, Oakland (N.P.K.), and the California Research Foundation, San Diego (D.M.B.) - both in California; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development, Pfizer, Pearl River (A.G., J.A., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.), and SUNY Upstate Medical University, Syracuse (S.J.T.) - both in New York; Vaccine Research and Development (J.L.P., H.M., X.X.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Duke Human Vaccine Institute, Durham, NC (E.B.W.); Senders Pediatrics, South Euclid, OH (S.S.); Clinical Research Professionals, Chesterfield, MO (T.J.); BioNTech, Mainz, Germany (Ö.T., U.Ş.); and Worldwide Safety, Safety Surveillance and Risk Management, Pfizer, Groton, CT (D.B.T.).
Kitchin N; From Cincinnati Children's Hospital, Cincinnati (R.W.F.); Kaiser Permanente Vaccine Study Center, Oakland (N.P.K.), and the California Research Foundation, San Diego (D.M.B.) - both in California; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development, Pfizer, Pearl River (A.G., J.A., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.), and SUNY Upstate Medical University, Syracuse (S.J.T.) - both in New York; Vaccine Research and Development (J.L.P., H.M., X.X.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Duke Human Vaccine Institute, Durham, NC (E.B.W.); Senders Pediatrics, South Euclid, OH (S.S.); Clinical Research Professionals, Chesterfield, MO (T.J.); BioNTech, Mainz, Germany (Ö.T., U.Ş.); and Worldwide Safety, Safety Surveillance and Risk Management, Pfizer, Groton, CT (D.B.T.).
Gurtman A; From Cincinnati Children's Hospital, Cincinnati (R.W.F.); Kaiser Permanente Vaccine Study Center, Oakland (N.P.K.), and the California Research Foundation, San Diego (D.M.B.) - both in California; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development, Pfizer, Pearl River (A.G., J.A., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.), and SUNY Upstate Medical University, Syracuse (S.J.T.) - both in New York; Vaccine Research and Development (J.L.P., H.M., X.X.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Duke Human Vaccine Institute, Durham, NC (E.B.W.); Senders Pediatrics, South Euclid, OH (S.S.); Clinical Research Professionals, Chesterfield, MO (T.J.); BioNTech, Mainz, Germany (Ö.T., U.Ş.); and Worldwide Safety, Safety Surveillance and Risk Management, Pfizer, Groton, CT (D.B.T.).
Absalon J; From Cincinnati Children's Hospital, Cincinnati (R.W.F.); Kaiser Permanente Vaccine Study Center, Oakland (N.P.K.), and the California Research Foundation, San Diego (D.M.B.) - both in California; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development, Pfizer, Pearl River (A.G., J.A., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.), and SUNY Upstate Medical University, Syracuse (S.J.T.) - both in New York; Vaccine Research and Development (J.L.P., H.M., X.X.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Duke Human Vaccine Institute, Durham, NC (E.B.W.); Senders Pediatrics, South Euclid, OH (S.S.); Clinical Research Professionals, Chesterfield, MO (T.J.); BioNTech, Mainz, Germany (Ö.T., U.Ş.); and Worldwide Safety, Safety Surveillance and Risk Management, Pfizer, Groton, CT (D.B.T.).
Lockhart S; From Cincinnati Children's Hospital, Cincinnati (R.W.F.); Kaiser Permanente Vaccine Study Center, Oakland (N.P.K.), and the California Research Foundation, San Diego (D.M.B.) - both in California; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development, Pfizer, Pearl River (A.G., J.A., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.), and SUNY Upstate Medical University, Syracuse (S.J.T.) - both in New York; Vaccine Research and Development (J.L.P., H.M., X.X.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Duke Human Vaccine Institute, Durham, NC (E.B.W.); Senders Pediatrics, South Euclid, OH (S.S.); Clinical Research Professionals, Chesterfield, MO (T.J.); BioNTech, Mainz, Germany (Ö.T., U.Ş.); and Worldwide Safety, Safety Surveillance and Risk Management, Pfizer, Groton, CT (D.B.T.).
Perez JL; From Cincinnati Children's Hospital, Cincinnati (R.W.F.); Kaiser Permanente Vaccine Study Center, Oakland (N.P.K.), and the California Research Foundation, San Diego (D.M.B.) - both in California; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development, Pfizer, Pearl River (A.G., J.A., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.), and SUNY Upstate Medical University, Syracuse (S.J.T.) - both in New York; Vaccine Research and Development (J.L.P., H.M., X.X.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Duke Human Vaccine Institute, Durham, NC (E.B.W.); Senders Pediatrics, South Euclid, OH (S.S.); Clinical Research Professionals, Chesterfield, MO (T.J.); BioNTech, Mainz, Germany (Ö.T., U.Ş.); and Worldwide Safety, Safety Surveillance and Risk Management, Pfizer, Groton, CT (D.B.T.).
Walter EB; From Cincinnati Children's Hospital, Cincinnati (R.W.F.); Kaiser Permanente Vaccine Study Center, Oakland (N.P.K.), and the California Research Foundation, San Diego (D.M.B.) - both in California; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development, Pfizer, Pearl River (A.G., J.A., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.), and SUNY Upstate Medical University, Syracuse (S.J.T.) - both in New York; Vaccine Research and Development (J.L.P., H.M., X.X.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Duke Human Vaccine Institute, Durham, NC (E.B.W.); Senders Pediatrics, South Euclid, OH (S.S.); Clinical Research Professionals, Chesterfield, MO (T.J.); BioNTech, Mainz, Germany (Ö.T., U.Ş.); and Worldwide Safety, Safety Surveillance and Risk Management, Pfizer, Groton, CT (D.B.T.).
Senders S; From Cincinnati Children's Hospital, Cincinnati (R.W.F.); Kaiser Permanente Vaccine Study Center, Oakland (N.P.K.), and the California Research Foundation, San Diego (D.M.B.) - both in California; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development, Pfizer, Pearl River (A.G., J.A., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.), and SUNY Upstate Medical University, Syracuse (S.J.T.) - both in New York; Vaccine Research and Development (J.L.P., H.M., X.X.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Duke Human Vaccine Institute, Durham, NC (E.B.W.); Senders Pediatrics, South Euclid, OH (S.S.); Clinical Research Professionals, Chesterfield, MO (T.J.); BioNTech, Mainz, Germany (Ö.T., U.Ş.); and Worldwide Safety, Safety Surveillance and Risk Management, Pfizer, Groton, CT (D.B.T.).
Bailey R; From Cincinnati Children's Hospital, Cincinnati (R.W.F.); Kaiser Permanente Vaccine Study Center, Oakland (N.P.K.), and the California Research Foundation, San Diego (D.M.B.) - both in California; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development, Pfizer, Pearl River (A.G., J.A., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.), and SUNY Upstate Medical University, Syracuse (S.J.T.) - both in New York; Vaccine Research and Development (J.L.P., H.M., X.X.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Duke Human Vaccine Institute, Durham, NC (E.B.W.); Senders Pediatrics, South Euclid, OH (S.S.); Clinical Research Professionals, Chesterfield, MO (T.J.); BioNTech, Mainz, Germany (Ö.T., U.Ş.); and Worldwide Safety, Safety Surveillance and Risk Management, Pfizer, Groton, CT (D.B.T.).
Swanson KA; From Cincinnati Children's Hospital, Cincinnati (R.W.F.); Kaiser Permanente Vaccine Study Center, Oakland (N.P.K.), and the California Research Foundation, San Diego (D.M.B.) - both in California; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development, Pfizer, Pearl River (A.G., J.A., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.), and SUNY Upstate Medical University, Syracuse (S.J.T.) - both in New York; Vaccine Research and Development (J.L.P., H.M., X.X.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Duke Human Vaccine Institute, Durham, NC (E.B.W.); Senders Pediatrics, South Euclid, OH (S.S.); Clinical Research Professionals, Chesterfield, MO (T.J.); BioNTech, Mainz, Germany (Ö.T., U.Ş.); and Worldwide Safety, Safety Surveillance and Risk Management, Pfizer, Groton, CT (D.B.T.).
Ma H; From Cincinnati Children's Hospital, Cincinnati (R.W.F.); Kaiser Permanente Vaccine Study Center, Oakland (N.P.K.), and the California Research Foundation, San Diego (D.M.B.) - both in California; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development, Pfizer, Pearl River (A.G., J.A., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.), and SUNY Upstate Medical University, Syracuse (S.J.T.) - both in New York; Vaccine Research and Development (J.L.P., H.M., X.X.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Duke Human Vaccine Institute, Durham, NC (E.B.W.); Senders Pediatrics, South Euclid, OH (S.S.); Clinical Research Professionals, Chesterfield, MO (T.J.); BioNTech, Mainz, Germany (Ö.T., U.Ş.); and Worldwide Safety, Safety Surveillance and Risk Management, Pfizer, Groton, CT (D.B.T.).
Xu X; From Cincinnati Children's Hospital, Cincinnati (R.W.F.); Kaiser Permanente Vaccine Study Center, Oakland (N.P.K.), and the California Research Foundation, San Diego (D.M.B.) - both in California; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development, Pfizer, Pearl River (A.G., J.A., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.), and SUNY Upstate Medical University, Syracuse (S.J.T.) - both in New York; Vaccine Research and Development (J.L.P., H.M., X.X.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Duke Human Vaccine Institute, Durham, NC (E.B.W.); Senders Pediatrics, South Euclid, OH (S.S.); Clinical Research Professionals, Chesterfield, MO (T.J.); BioNTech, Mainz, Germany (Ö.T., U.Ş.); and Worldwide Safety, Safety Surveillance and Risk Management, Pfizer, Groton, CT (D.B.T.).
Koury K; From Cincinnati Children's Hospital, Cincinnati (R.W.F.); Kaiser Permanente Vaccine Study Center, Oakland (N.P.K.), and the California Research Foundation, San Diego (D.M.B.) - both in California; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development, Pfizer, Pearl River (A.G., J.A., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.), and SUNY Upstate Medical University, Syracuse (S.J.T.) - both in New York; Vaccine Research and Development (J.L.P., H.M., X.X.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Duke Human Vaccine Institute, Durham, NC (E.B.W.); Senders Pediatrics, South Euclid, OH (S.S.); Clinical Research Professionals, Chesterfield, MO (T.J.); BioNTech, Mainz, Germany (Ö.T., U.Ş.); and Worldwide Safety, Safety Surveillance and Risk Management, Pfizer, Groton, CT (D.B.T.).
Kalina WV; From Cincinnati Children's Hospital, Cincinnati (R.W.F.); Kaiser Permanente Vaccine Study Center, Oakland (N.P.K.), and the California Research Foundation, San Diego (D.M.B.) - both in California; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development, Pfizer, Pearl River (A.G., J.A., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.), and SUNY Upstate Medical University, Syracuse (S.J.T.) - both in New York; Vaccine Research and Development (J.L.P., H.M., X.X.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Duke Human Vaccine Institute, Durham, NC (E.B.W.); Senders Pediatrics, South Euclid, OH (S.S.); Clinical Research Professionals, Chesterfield, MO (T.J.); BioNTech, Mainz, Germany (Ö.T., U.Ş.); and Worldwide Safety, Safety Surveillance and Risk Management, Pfizer, Groton, CT (D.B.T.).
Cooper D; From Cincinnati Children's Hospital, Cincinnati (R.W.F.); Kaiser Permanente Vaccine Study Center, Oakland (N.P.K.), and the California Research Foundation, San Diego (D.M.B.) - both in California; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development, Pfizer, Pearl River (A.G., J.A., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.), and SUNY Upstate Medical University, Syracuse (S.J.T.) - both in New York; Vaccine Research and Development (J.L.P., H.M., X.X.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Duke Human Vaccine Institute, Durham, NC (E.B.W.); Senders Pediatrics, South Euclid, OH (S.S.); Clinical Research Professionals, Chesterfield, MO (T.J.); BioNTech, Mainz, Germany (Ö.T., U.Ş.); and Worldwide Safety, Safety Surveillance and Risk Management, Pfizer, Groton, CT (D.B.T.).
Jennings T; From Cincinnati Children's Hospital, Cincinnati (R.W.F.); Kaiser Permanente Vaccine Study Center, Oakland (N.P.K.), and the California Research Foundation, San Diego (D.M.B.) - both in California; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development, Pfizer, Pearl River (A.G., J.A., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.), and SUNY Upstate Medical University, Syracuse (S.J.T.) - both in New York; Vaccine Research and Development (J.L.P., H.M., X.X.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Duke Human Vaccine Institute, Durham, NC (E.B.W.); Senders Pediatrics, South Euclid, OH (S.S.); Clinical Research Professionals, Chesterfield, MO (T.J.); BioNTech, Mainz, Germany (Ö.T., U.Ş.); and Worldwide Safety, Safety Surveillance and Risk Management, Pfizer, Groton, CT (D.B.T.).
Brandon DM; From Cincinnati Children's Hospital, Cincinnati (R.W.F.); Kaiser Permanente Vaccine Study Center, Oakland (N.P.K.), and the California Research Foundation, San Diego (D.M.B.) - both in California; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development, Pfizer, Pearl River (A.G., J.A., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.), and SUNY Upstate Medical University, Syracuse (S.J.T.) - both in New York; Vaccine Research and Development (J.L.P., H.M., X.X.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Duke Human Vaccine Institute, Durham, NC (E.B.W.); Senders Pediatrics, South Euclid, OH (S.S.); Clinical Research Professionals, Chesterfield, MO (T.J.); BioNTech, Mainz, Germany (Ö.T., U.Ş.); and Worldwide Safety, Safety Surveillance and Risk Management, Pfizer, Groton, CT (D.B.T.).
Thomas SJ; From Cincinnati Children's Hospital, Cincinnati (R.W.F.); Kaiser Permanente Vaccine Study Center, Oakland (N.P.K.), and the California Research Foundation, San Diego (D.M.B.) - both in California; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development, Pfizer, Pearl River (A.G., J.A., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.), and SUNY Upstate Medical University, Syracuse (S.J.T.) - both in New York; Vaccine Research and Development (J.L.P., H.M., X.X.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Duke Human Vaccine Institute, Durham, NC (E.B.W.); Senders Pediatrics, South Euclid, OH (S.S.); Clinical Research Professionals, Chesterfield, MO (T.J.); BioNTech, Mainz, Germany (Ö.T., U.Ş.); and Worldwide Safety, Safety Surveillance and Risk Management, Pfizer, Groton, CT (D.B.T.).
Türeci Ö; From Cincinnati Children's Hospital, Cincinnati (R.W.F.); Kaiser Permanente Vaccine Study Center, Oakland (N.P.K.), and the California Research Foundation, San Diego (D.M.B.) - both in California; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development, Pfizer, Pearl River (A.G., J.A., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.), and SUNY Upstate Medical University, Syracuse (S.J.T.) - both in New York; Vaccine Research and Development (J.L.P., H.M., X.X.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Duke Human Vaccine Institute, Durham, NC (E.B.W.); Senders Pediatrics, South Euclid, OH (S.S.); Clinical Research Professionals, Chesterfield, MO (T.J.); BioNTech, Mainz, Germany (Ö.T., U.Ş.); and Worldwide Safety, Safety Surveillance and Risk Management, Pfizer, Groton, CT (D.B.T.).
Tresnan DB; From Cincinnati Children's Hospital, Cincinnati (R.W.F.); Kaiser Permanente Vaccine Study Center, Oakland (N.P.K.), and the California Research Foundation, San Diego (D.M.B.) - both in California; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development, Pfizer, Pearl River (A.G., J.A., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.), and SUNY Upstate Medical University, Syracuse (S.J.T.) - both in New York; Vaccine Research and Development (J.L.P., H.M., X.X.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Duke Human Vaccine Institute, Durham, NC (E.B.W.); Senders Pediatrics, South Euclid, OH (S.S.); Clinical Research Professionals, Chesterfield, MO (T.J.); BioNTech, Mainz, Germany (Ö.T., U.Ş.); and Worldwide Safety, Safety Surveillance and Risk Management, Pfizer, Groton, CT (D.B.T.).
Mather S; From Cincinnati Children's Hospital, Cincinnati (R.W.F.); Kaiser Permanente Vaccine Study Center, Oakland (N.P.K.), and the California Research Foundation, San Diego (D.M.B.) - both in California; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development, Pfizer, Pearl River (A.G., J.A., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.), and SUNY Upstate Medical University, Syracuse (S.J.T.) - both in New York; Vaccine Research and Development (J.L.P., H.M., X.X.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Duke Human Vaccine Institute, Durham, NC (E.B.W.); Senders Pediatrics, South Euclid, OH (S.S.); Clinical Research Professionals, Chesterfield, MO (T.J.); BioNTech, Mainz, Germany (Ö.T., U.Ş.); and Worldwide Safety, Safety Surveillance and Risk Management, Pfizer, Groton, CT (D.B.T.).
Dormitzer PR; From Cincinnati Children's Hospital, Cincinnati (R.W.F.); Kaiser Permanente Vaccine Study Center, Oakland (N.P.K.), and the California Research Foundation, San Diego (D.M.B.) - both in California; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development, Pfizer, Pearl River (A.G., J.A., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.), and SUNY Upstate Medical University, Syracuse (S.J.T.) - both in New York; Vaccine Research and Development (J.L.P., H.M., X.X.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Duke Human Vaccine Institute, Durham, NC (E.B.W.); Senders Pediatrics, South Euclid, OH (S.S.); Clinical Research Professionals, Chesterfield, MO (T.J.); BioNTech, Mainz, Germany (Ö.T., U.Ş.); and Worldwide Safety, Safety Surveillance and Risk Management, Pfizer, Groton, CT (D.B.T.).
Şahin U; From Cincinnati Children's Hospital, Cincinnati (R.W.F.); Kaiser Permanente Vaccine Study Center, Oakland (N.P.K.), and the California Research Foundation, San Diego (D.M.B.) - both in California; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development, Pfizer, Pearl River (A.G., J.A., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.), and SUNY Upstate Medical University, Syracuse (S.J.T.) - both in New York; Vaccine Research and Development (J.L.P., H.M., X.X.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Duke Human Vaccine Institute, Durham, NC (E.B.W.); Senders Pediatrics, South Euclid, OH (S.S.); Clinical Research Professionals, Chesterfield, MO (T.J.); BioNTech, Mainz, Germany (Ö.T., U.Ş.); and Worldwide Safety, Safety Surveillance and Risk Management, Pfizer, Groton, CT (D.B.T.).
Jansen KU; From Cincinnati Children's Hospital, Cincinnati (R.W.F.); Kaiser Permanente Vaccine Study Center, Oakland (N.P.K.), and the California Research Foundation, San Diego (D.M.B.) - both in California; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development, Pfizer, Pearl River (A.G., J.A., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.), and SUNY Upstate Medical University, Syracuse (S.J.T.) - both in New York; Vaccine Research and Development (J.L.P., H.M., X.X.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Duke Human Vaccine Institute, Durham, NC (E.B.W.); Senders Pediatrics, South Euclid, OH (S.S.); Clinical Research Professionals, Chesterfield, MO (T.J.); BioNTech, Mainz, Germany (Ö.T., U.Ş.); and Worldwide Safety, Safety Surveillance and Risk Management, Pfizer, Groton, CT (D.B.T.).
Gruber WC; From Cincinnati Children's Hospital, Cincinnati (R.W.F.); Kaiser Permanente Vaccine Study Center, Oakland (N.P.K.), and the California Research Foundation, San Diego (D.M.B.) - both in California; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development, Pfizer, Pearl River (A.G., J.A., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.), and SUNY Upstate Medical University, Syracuse (S.J.T.) - both in New York; Vaccine Research and Development (J.L.P., H.M., X.X.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Duke Human Vaccine Institute, Durham, NC (E.B.W.); Senders Pediatrics, South Euclid, OH (S.S.); Clinical Research Professionals, Chesterfield, MO (T.J.); BioNTech, Mainz, Germany (Ö.T., U.Ş.); and Worldwide Safety, Safety Surveillance and Risk Management, Pfizer, Groton, CT (D.B.T.).
Pokaż więcej
Corporate Authors :
C4591001 Clinical Trial Group
Źródło :
The New England journal of medicine [N Engl J Med] 2021 Jul 15; Vol. 385 (3), pp. 239-250. Date of Electronic Publication: 2021 May 27.
Typ publikacji :
Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Immunogenicity, Vaccine*
Antibodies, Neutralizing/*blood
Antibodies, Viral/*blood
COVID-19/*prevention & control
COVID-19 Vaccines/*immunology
Adolescent ; Adult ; Age Factors ; COVID-19 Vaccines/administration & dosage ; COVID-19 Vaccines/adverse effects ; Child ; Female ; Humans ; Immunoglobulin G/blood ; Injections, Intramuscular/adverse effects ; Male ; Pain/etiology ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
COVID-19 vaccine access in Africa: Global distribution, vaccine platforms, and challenges ahead.
Autorzy :
Massinga Loembé M; Africa Centers for Disease Control and Prevention, P.O. Box 3243, Addis Ababa, Ethiopia.
Nkengasong JN; Africa Centers for Disease Control and Prevention, P.O. Box 3243, Addis Ababa, Ethiopia. Electronic address: .
Pokaż więcej
Źródło :
Immunity [Immunity] 2021 Jul 13; Vol. 54 (7), pp. 1353-1362.
Typ publikacji :
Journal Article
MeSH Terms :
COVID-19 Vaccines/*supply & distribution
Health Services Accessibility/*statistics & numerical data
SARS-CoV-2/*immunology
Africa/epidemiology ; COVID-19/epidemiology ; COVID-19/prevention & control ; COVID-19 Vaccines/administration & dosage ; COVID-19 Vaccines/classification ; Global Health ; Health Services Accessibility/organization & administration ; Health Services Accessibility/trends ; Humans ; Vaccination/statistics & numerical data ; Vaccination/trends
Czasopismo naukowe
Tytuł :
Vaccination of cancer patients against COVID-19: towards the end of a dilemma.
Autorzy :
Mandal A; Department of Radiation Oncology, All India Institute of Medical Sciences, Aurangabad Road, Phulwari Sharif, Patna, Bihar, 801507, India. .
Singh P; Department of Radiation Oncology, All India Institute of Medical Sciences, Aurangabad Road, Phulwari Sharif, Patna, Bihar, 801507, India.
Samaddar A; Depratment of Neuromicrobiology, National Institute of Mental Health & Neurosciences, Bengaluru, Karnataka, India.
Singh D; Department of Radiation Oncology, All India Institute of Medical Sciences, Aurangabad Road, Phulwari Sharif, Patna, Bihar, 801507, India.
Verma M; Department of Radiation Oncology, All India Institute of Medical Sciences, Aurangabad Road, Phulwari Sharif, Patna, Bihar, 801507, India.
Rakesh A; Department of Radiation Oncology, All India Institute of Medical Sciences, Aurangabad Road, Phulwari Sharif, Patna, Bihar, 801507, India.
Ranjan R; Department of Radiation Oncology, All India Institute of Medical Sciences, Aurangabad Road, Phulwari Sharif, Patna, Bihar, 801507, India.
Pokaż więcej
Źródło :
Medical oncology (Northwood, London, England) [Med Oncol] 2021 Jul 08; Vol. 38 (8), pp. 92. Date of Electronic Publication: 2021 Jul 08.
Typ publikacji :
Journal Article; Review
MeSH Terms :
COVID-19 Vaccines*
Vaccination*
COVID-19/*prevention & control
Neoplasms/*therapy
Humans ; SARS-CoV-2
Czasopismo naukowe
Tytuł :
Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants.
Autorzy :
Abu-Raddad LJ; Weill Cornell Medicine-Qatar, Doha, Qatar .
Chemaitelly H; Weill Cornell Medicine-Qatar, Doha, Qatar .
Butt AA; Hamad Medical Corporation, Doha, Qatar.
Pokaż więcej
Corporate Authors :
National Study Group for COVID-19 Vaccination
Źródło :
The New England journal of medicine [N Engl J Med] 2021 Jul 08; Vol. 385 (2), pp. 187-189. Date of Electronic Publication: 2021 May 05.
Typ publikacji :
Letter; Research Support, Non-U.S. Gov't
MeSH Terms :
COVID-19 Vaccines*/administration & dosage
COVID-19 Vaccines*/immunology
Immunogenicity, Vaccine*
SARS-CoV-2*
COVID-19/*prevention & control
COVID-19/diagnosis ; COVID-19/mortality ; COVID-19/virology ; Case-Control Studies ; Cohort Studies ; Humans ; Polymerase Chain Reaction ; Qatar/epidemiology ; Treatment Outcome
SCR Organism :
SARS-CoV-2 variants
Raport
Tytuł :
Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial.
Autorzy :
Al Kaabi N; Sheikh Khalifa Medical City, Abu Dhabi Health Services Company (SEHA), Abu Dhabi, United Arab Emirates.
Zhang Y; China National Biotec Group Company Limited, Beijing, China.
Xia S; Henan Province Center for Disease Control and Prevention, Zhengzhou, Henan, China.
Yang Y; China National Biotec Group Company Limited, Beijing, China.
Al Qahtani MM; Bahrain Defence Force Royal Medical Services, Military Hospital, Kingdom of Bahrain.
Abdulrazzaq N; Ministry of Health and Prevention, Abu Dhabi, United Arab Emirates.
Al Nusair M; Prince Hamza Hospital, Amman, Jordan.
Hassany M; Ministry of Health, Cairo, Egypt.
Jawad JS; Ministry of Health, Kingdom of Bahrain.
Abdalla J; Sheikh Khalifa Medical City, Abu Dhabi Health Services Company (SEHA), Abu Dhabi, United Arab Emirates.
Hussein SE; Sheikh Khalifa Medical City, Abu Dhabi Health Services Company (SEHA), Abu Dhabi, United Arab Emirates.
Al Mazrouei SK; Sheikh Khalifa Medical City, Abu Dhabi Health Services Company (SEHA), Abu Dhabi, United Arab Emirates.
Al Karam M; Sheikh Khalifa Medical City, Abu Dhabi Health Services Company (SEHA), Abu Dhabi, United Arab Emirates.
Li X; National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co, Ltd, Wuhan, Hubei, China.
Yang X; China National Biotec Group Company Limited, Beijing, China.
Wang W; Beijing Institute of Biological Products Co, Ltd, Beijing, China.
Lai B; China National Biotec Group Company Limited, Beijing, China.
Chen W; National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co, Ltd, Wuhan, Hubei, China.
Huang S; National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co, Ltd, Wuhan, Hubei, China.
Wang Q; China National Biotec Group Company Limited, Beijing, China.
Yang T; China National Biotec Group Company Limited, Beijing, China.
Liu Y; China National Biotec Group Company Limited, Beijing, China.
Ma R; Beijing Institute of Biological Products Co, Ltd, Beijing, China.
Hussain ZM; Sheikh Khalifa Medical City, Abu Dhabi Health Services Company (SEHA), Abu Dhabi, United Arab Emirates.
Khan T; Sheikh Khalifa Medical City, Abu Dhabi Health Services Company (SEHA), Abu Dhabi, United Arab Emirates.
Saifuddin Fasihuddin M; Sheikh Khalifa Medical City, Abu Dhabi Health Services Company (SEHA), Abu Dhabi, United Arab Emirates.
You W; Henan Province Center for Disease Control and Prevention, Zhengzhou, Henan, China.
Xie Z; Henan Province Center for Disease Control and Prevention, Zhengzhou, Henan, China.
Zhao Y; Beijing Institute of Biological Products Co, Ltd, Beijing, China.
Jiang Z; Beijing Key-Tech Statistical Consulting Co, Ltd, Beijing, China.
Zhao G; Beijing Key-Tech Statistical Consulting Co, Ltd, Beijing, China.
Zhang Y; Department of Epidemiology and Biostatistics, Ministry of Education Key Laboratory of Environment and Health and State Key Laboratory of Environmental Health (incubation), School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Mahmoud S; G42 Healthcare, Abu Dhabi, United Arab Emirates.
ElTantawy I; G42 Healthcare, Abu Dhabi, United Arab Emirates.
Xiao P; G42 Healthcare, Abu Dhabi, United Arab Emirates.
Koshy A; Department of Epidemiology and Biostatistics, Ministry of Education Key Laboratory of Environment and Health and State Key Laboratory of Environmental Health (incubation), School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Zaher WA; G42 Healthcare, Abu Dhabi, United Arab Emirates.
Wang H; Beijing Institute of Biological Products Co, Ltd, Beijing, China.
Duan K; National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co, Ltd, Wuhan, Hubei, China.
Pan A; Department of Epidemiology and Biostatistics, Ministry of Education Key Laboratory of Environment and Health and State Key Laboratory of Environmental Health (incubation), School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Yang X; China National Biotec Group Company Limited, Beijing, China.; National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co, Ltd, Wuhan, Hubei, China.
Pokaż więcej
Źródło :
JAMA [JAMA] 2021 Jul 06; Vol. 326 (1), pp. 35-45.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms :
Immunogenicity, Vaccine*
COVID-19/*prevention & control
COVID-19 Vaccines/*immunology
Adult ; COVID-19/immunology ; COVID-19 Vaccines/administration & dosage ; COVID-19 Vaccines/adverse effects ; Datasets as Topic ; Double-Blind Method ; Female ; Humans ; Injections, Intramuscular ; Male ; Middle Aged ; Middle East ; Vaccines, Inactivated/immunology
Czasopismo naukowe
Tytuł :
Mounting evidence suggests Sputnik COVID vaccine is safe and effective.
Autorzy :
Nogrady B
Pokaż więcej
Źródło :
Nature [Nature] 2021 Jul; Vol. 595 (7867), pp. 339-340.
Typ publikacji :
Wiadomości
MeSH Terms :
Safety*
COVID-19/*prevention & control
COVID-19 Vaccines/*adverse effects
COVID-19 Vaccines/*immunology
SARS-CoV-2/*immunology
Aged ; COVID-19/immunology ; COVID-19 Vaccines/supply & distribution ; Drug Approval ; Humans ; Internationality ; Middle Aged ; Russia ; World Health Organization
Periodyk
Tytuł :
An update review of globally reported SARS-CoV-2 vaccines in preclinical and clinical stages.
Autorzy :
Motamedi H; Department of Microbiology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Ari MM; Department of Microbiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Dashtbin S; Department of Microbiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Fathollahi M; Department of Microbiology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Hossainpour H; Department of Microbiology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Alvandi A; Department of Microbiology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran; Medical Technology Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Moradi J; Department of Microbiology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Abiri R; Department of Microbiology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran; Fertility and Infertility Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran. Electronic address: .
Pokaż więcej
Źródło :
International immunopharmacology [Int Immunopharmacol] 2021 Jul; Vol. 96, pp. 107763. Date of Electronic Publication: 2021 May 06.
Typ publikacji :
Journal Article; Review
MeSH Terms :
COVID-19/*immunology
COVID-19/*prevention & control
COVID-19 Vaccines/*immunology
SARS-CoV-2/*immunology
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Animals ; BCG Vaccine/immunology ; COVID-19 Vaccines/administration & dosage ; COVID-19 Vaccines/adverse effects ; Drug Evaluation, Preclinical ; Female ; Humans ; Male ; Meta-Analysis as Topic ; Middle Aged ; Vaccines, DNA/immunology ; Vaccines, Inactivated/immunology ; Vaccines, Subunit/immunology ; Vaccines, Virus-Like Particle/immunology ; Viral Vaccines/immunology
Czasopismo naukowe
Tytuł :
Antibody response to SARS-CoV-2 vaccination is extremely vivacious in subjects with previous SARS-CoV-2 infection.
Autorzy :
Callegaro A; Department of Laboratory Medicine, Biobank, ASST Papa Giovanni XXIII, Bergamo, Italy.; Department of Laboratory Medicine, Microbiology and Virology, ASST Papa Giovanni XXIII, Bergamo, Italy.
Borleri D; Department of Occupational Medicine, ASST Papa Giovanni XXIII, Bergamo, Italy.
Farina C; Department of Laboratory Medicine, Microbiology and Virology, ASST Papa Giovanni XXIII, Bergamo, Italy.
Napolitano G; Department of Laboratory Medicine, Biobank, ASST Papa Giovanni XXIII, Bergamo, Italy.; Department of Laboratory Medicine, Microbiology and Virology, ASST Papa Giovanni XXIII, Bergamo, Italy.
Valenti D; FROM Foundation, ASST Papa Giovanni XXIII, Bergamo, Italy.; Division of Infectious Diseases, ASST Papa Giovanni XXIII, Bergamo, Italy.
Rizzi M; Division of Infectious Diseases, ASST Papa Giovanni XXIII, Bergamo, Italy.
Maggiolo F; Division of Infectious Diseases, ASST Papa Giovanni XXIII, Bergamo, Italy.
Pokaż więcej
Źródło :
Journal of medical virology [J Med Virol] 2021 Jul; Vol. 93 (7), pp. 4612-4615. Date of Electronic Publication: 2021 Apr 08.
Typ publikacji :
Journal Article
MeSH Terms :
Antibodies, Viral/*immunology
COVID-19/*immunology
COVID-19 Vaccines/*immunology
SARS-CoV-2/*immunology
Adult ; Antibodies, Viral/blood ; Asymptomatic Infections ; COVID-19/diagnosis ; COVID-19/prevention & control ; COVID-19 Vaccines/administration & dosage ; COVID-19 Vaccines/adverse effects ; Female ; Health Personnel ; Humans ; Immunization Schedule ; Immunization, Secondary ; Male ; Middle Aged ; SARS-CoV-2/isolation & purification ; Spike Glycoprotein, Coronavirus/immunology ; Vaccination ; Vaccines, Synthetic/administration & dosage ; Vaccines, Synthetic/adverse effects ; Vaccines, Synthetic/immunology
Czasopismo naukowe
Tytuł :
Perspectives on vaccine induced thrombotic thrombocytopenia.
Autorzy :
Dotan A; Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Ramat-Gan, 52621, Israel. Electronic address: .
Shoenfeld Y; Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Ramat-Gan, 52621, Israel; Ariel University, Ariel, Israel; I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russia.
Pokaż więcej
Źródło :
Journal of autoimmunity [J Autoimmun] 2021 Jul; Vol. 121, pp. 102663. Date of Electronic Publication: 2021 May 18.
Typ publikacji :
Journal Article; Review
MeSH Terms :
COVID-19/*immunology
COVID-19 Vaccines/*adverse effects
Purpura, Thrombocytopenic, Idiopathic/*immunology
SARS-CoV-2/*immunology
Antigens, Viral/immunology ; Autoantibodies/immunology ; COVID-19/pathology ; COVID-19/prevention & control ; COVID-19 Vaccines/immunology ; COVID-19 Vaccines/therapeutic use ; Humans ; Platelet Factor 4/immunology ; Purpura, Thrombocytopenic, Idiopathic/chemically induced ; Purpura, Thrombocytopenic, Idiopathic/pathology
Czasopismo naukowe
Tytuł :
Nucleoside-modified messenger RNA COVID-19 vaccine platform.
Autorzy :
Roncati L; Department of Surgery, Medicine, Dentistry and Morphological Sciences with interest in Transplantation, Oncology and Regenerative Medicine, Institute of Pathology, University of Modena and Reggio Emilia, Modena, Italy.
Corsi L; Department of Life Sciences, Section of Pharmacology, University of Modena and Reggio Emilia, Modena, Italy.
Pokaż więcej
Źródło :
Journal of medical virology [J Med Virol] 2021 Jul; Vol. 93 (7), pp. 4054-4057. Date of Electronic Publication: 2021 Mar 25.
Typ publikacji :
Journal Article
MeSH Terms :
COVID-19 Vaccines*/administration & dosage
COVID-19 Vaccines*/adverse effects
COVID-19 Vaccines*/immunology
Vaccines, Synthetic*/administration & dosage
Vaccines, Synthetic*/adverse effects
Vaccines, Synthetic*/immunology
COVID-19/*prevention & control
Humans ; Hypersensitivity/etiology ; Liposomes/adverse effects ; Nanoparticles/adverse effects ; Nucleosides ; Pandemics/prevention & control ; Pharmacovigilance ; Polyethylene Glycols/adverse effects ; RNA, Messenger/chemistry
Czasopismo naukowe
Tytuł :
A recommended paradigm for vaccination of rheumatic disease patients with the SARS-CoV-2 vaccine.
Autorzy :
Moutsopoulos HM; Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens and Academy of Athens, Athens, Greece. Electronic address: .
Pokaż więcej
Źródło :
Journal of autoimmunity [J Autoimmun] 2021 Jul; Vol. 121, pp. 102649. Date of Electronic Publication: 2021 May 01.
Typ publikacji :
Journal Article; Review
MeSH Terms :
COVID-19*/immunology
COVID-19*/prevention & control
COVID-19 Vaccines*/immunology
COVID-19 Vaccines*/therapeutic use
Immunosuppression*
Rheumatic Diseases*/immunology
Rheumatic Diseases*/therapy
Vaccination*
SARS-CoV-2/*immunology
Cytokines/isolation & purification ; Humans ; Pneumococcal Vaccines/immunology ; Pneumococcal Vaccines/therapeutic use
Czasopismo naukowe
Tytuł :
Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine.
Autorzy :
Lebedev L; Departments of Nephrology and Hypertension, Barzilai University Medical Center, Ashkelon, Israel; Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheba, Israel.
Sapojnikov M; Departments of Nephrology and Hypertension, Barzilai University Medical Center, Ashkelon, Israel; Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheba, Israel.
Wechsler A; Departments of Nephrology and Hypertension, Barzilai University Medical Center, Ashkelon, Israel; Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheba, Israel.
Varadi-Levi R; Departments of Nephrology and Hypertension, Barzilai University Medical Center, Ashkelon, Israel; Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheba, Israel.
Zamir D; Department of Medicine D, Barzilai University Medical Center, Ashkelon, Israel; Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheba, Israel.
Tobar A; Department of Pathology, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel.
Levin-Iaina N; Departments of Nephrology and Hypertension, Barzilai University Medical Center, Ashkelon, Israel.
Fytlovich S; Department of Medical Laboratories, Barzilai University Medical Center, Ashkelon, Israel.
Yagil Y; Departments of Nephrology and Hypertension, Barzilai University Medical Center, Ashkelon, Israel; Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheba, Israel. Electronic address: .
Pokaż więcej
Źródło :
American journal of kidney diseases : the official journal of the National Kidney Foundation [Am J Kidney Dis] 2021 Jul; Vol. 78 (1), pp. 142-145. Date of Electronic Publication: 2021 Apr 08.
Typ publikacji :
Case Reports
MeSH Terms :
Acute Kidney Injury*/etiology
Acute Kidney Injury*/pathology
COVID-19 Vaccines*/administration & dosage
COVID-19 Vaccines*/adverse effects
Nephrosis, Lipoid*/diagnosis
Nephrosis, Lipoid*/drug therapy
Nephrosis, Lipoid*/etiology
Nephrosis, Lipoid*/physiopathology
Nephrotic Syndrome*/diagnosis
Nephrotic Syndrome*/etiology
COVID-19/*prevention & control
Prednisone/*administration & dosage
Biopsy/methods ; COVID-19/epidemiology ; Creatinine/blood ; Edema/diagnosis ; Edema/etiology ; Glucocorticoids/administration & dosage ; Humans ; Male ; Middle Aged ; Renal Elimination/drug effects ; SARS-CoV-2 ; Treatment Outcome ; Urinalysis/methods
Raport
Tytuł :
Vaccination hesitancy and the "myth" on mRNA-based vaccines in Italy in the COVID-19 era: Does urgency meet major safety criteria?
Autorzy :
Chirumbolo S; Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.
Pokaż więcej
Źródło :
Journal of medical virology [J Med Virol] 2021 Jul; Vol. 93 (7), pp. 4049-4053. Date of Electronic Publication: 2021 Mar 25.
Typ publikacji :
Journal Article
MeSH Terms :
COVID-19 Vaccines*/adverse effects
COVID-19 Vaccines*/immunology
Vaccination Refusal*
Vaccines, Synthetic*/adverse effects
Vaccines, Synthetic*/immunology
COVID-19/*prevention & control
Anaphylaxis/etiology ; COVID-19/epidemiology ; COVID-19/immunology ; Health Knowledge, Attitudes, Practice ; Humans ; Italy/epidemiology ; Liposomes/adverse effects ; Mass Vaccination ; Nanoparticles/adverse effects ; Pandemics/prevention & control ; Polyethylene Glycols/adverse effects
Czasopismo naukowe
Tytuł :
Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: Causality or casualty?
Autorzy :
Bril F; Internal Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address: .
Al Diffalha S; Division of Anatomic Pathology, Department of Pathology, University of Alabama at Birmingham, Birmingham, AL, USA.
Dean M; Internal Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Fettig DM; Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Pokaż więcej
Źródło :
Journal of hepatology [J Hepatol] 2021 Jul; Vol. 75 (1), pp. 222-224. Date of Electronic Publication: 2021 Apr 20.
Typ publikacji :
Case Reports; Letter
MeSH Terms :
COVID-19 Vaccines*/administration & dosage
COVID-19 Vaccines*/adverse effects
Hepatitis, Autoimmune*/diagnosis
Hepatitis, Autoimmune*/immunology
Hepatitis, Autoimmune*/physiopathology
Hepatitis, Autoimmune*/therapy
Liver*/diagnostic imaging
Liver*/pathology
Antibodies, Antinuclear/*blood
COVID-19/*prevention & control
Prednisone/*administration & dosage
Adult ; Biopsy/methods ; COVID-19/epidemiology ; DNA/immunology ; Endosonography/methods ; Female ; Glucocorticoids/administration & dosage ; Humans ; Liver Function Tests/methods ; Postpartum Period ; SARS-CoV-2 ; Treatment Outcome
Raport
Tytuł :
Scientific Understanding of COVID-19: The First Step to Vanquishing the Current Pandemic.
Autorzy :
Shin EC; Laboratory of Immunology and Infectious Diseases, Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 34141, Korea.; The Center for Epidemic Preparedness, KAIST, Daejeon 34141, Korea.
Pokaż więcej
Źródło :
Molecules and cells [Mol Cells] 2021 Jun 30; Vol. 44 (6), pp. 375-376.
Typ publikacji :
Editorial; Introductory Journal Article
MeSH Terms :
COVID-19/*epidemiology
COVID-19 Vaccines/*therapeutic use
Pandemics/*prevention & control
COVID-19/mortality ; COVID-19/prevention & control ; COVID-19 Vaccines/classification ; COVID-19 Vaccines/immunology ; Global Health ; Humans ; SARS-CoV-2/immunology ; SARS-CoV-2/pathogenicity
SCR Organism :
SARS-CoV-2 variants
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies